Apr 2, 2019 — 3 min read
Seoul, Korea—Lunit, a leading medical AI startup that provides AI solutions for radiology and pathology, announced today its attendance at the Society of Breast Imaging (SBI) 2019, scheduled to showcase its latest product for breast cancer detection, Lunit INSIGHT for Mammography.
According to Lunit, the product is soon to be available for commercial sales, as the company is expecting to gain regulatory approvals in different regions, beginning this July.
“We are very much excited about the imminent regulatory clearance for our AI solution for mammography, which will happen as early as July,” said Brandon Suh, CEO of Lunit. “We are looking forward to Korea Ministry of Food and Drug Safety (MFDS) approval by July, followed by CE approval by September and FDA approval by early 2020.”
Lunit INSIGHT for Mammography was first revealed during RSNA 2018, presenting an unprecedented level of accuracy in the detection of breast cancer, at 97%. “While breast cancer takes up 25% of entire cancer cases, the accuracy of screening mammography is low by 32%,” said Suh. “False negative rates range from 10-30% and false positive rates are even higher at around 95%. This costs over 4 billion US dollars for unnecessary recalls in the United States alone. We target to reduce this cost by pulling more accurate information from cheap and accessible basic tests, being able to utilize these as clinically actionable information that can increase efficiency in diagnostics.”
Lunit INSIGHT for Mammography will be available for demonstration at booth #402 during SBI 2019, which will be held from 4-7 April at Hollywood, Florida.
Lunit is also developing a more sophisticated AI solution for Digital Breast Tomosynthesis (DBT), which has been demonstrated by various large-scale studies to be superior to mammography in terms of breast cancer screening performance.
“While our AI solution for mammography is now headed for commercial release, we are continuing our research and development for other modalities to meet greater needs in breast cancer detection,” said Hyo Eun Kim, Head of Breast Radiography at Lunit. “We are using our experience in mammography research to develop a highly accurate diagnostic algorithm for breast cancer detection in DBT.”
The first product release by Lunit—an AI solution for chest radiography—which had acquired Korea MFDS approval in August 2018, is currently available for clinical use in Korea. It has customers ranging from Seoul National University Hospital, one of the largest medical center in Korea, to small and large medical examination centers in the country. It is also currently used in hospitals in Mexico and UAE.
Lunit wins Tumor Proliferation Assessment Challenge (TUPAC) 2016
Lunit to unveil data-driven imaging biomarker at RSNA 2016
Lunit to showcase AI-powered products at USCAP 2017
Lunit INSIGHT: The First-ever, Real-time Imaging AI Analytics on the Web
Cognitive biases and augmented intelligence in radiology
Lunit Returns to RSNA with Real-time Imaging Platform, Featuring Cloud-based A
Lunit Unveils “Lunit INSIGHT,” A New Real-time Imaging AI Platform on the Web at RSNA 2017
Lunit INSIGHT: Q&A with Brandon B. Suh, Chief Medical Officer at Lunit
Media Advisory: Lunit at RSNA 2018
Lunit Opens “Lunit INSIGHT for Mammography” for Public Access
Lunit Brings its Newest AI Solution for Mammography to RSNA 2018
Lunit Partners with Fujifilm and Salud Digna to Provide Medical AI Solution in Mexico
Lunit announces new members in its advisory board: Dr. Eliot Siegel, Dr. Linda Moy, and Dr. Khan Siddiqui
Lunit to Introduce Medical AI Solutions at GTC 2019
Lunit to Present Abstracts on AI-powered Precision Pathology at 2019 AACR Annual Meeting
Lunit to Present Findings on the Predictive Power of AI Biomarker for Lung Cancer Immunotherapy at ASCO 2019
Lunit Receives Korea MFDS Approval for its AI Solution for Breast Cancer, Lunit INSIGHT MMG
Lunit Gets Korea MFDS Approval for its AI Solution for Chest X-ray, Lunit INSIGHT CXR 2
Lunit at RSNA 2019
Lunit Announces its First CE Mark for AI-Powered Chest X-ray Analysis Software, Lunit INSIGHT CXR
Lunit AI software clinically installed in global sites—to be presented at RSNA 2019
AI-assisted Radiologists Can Detect More Breast Cancer with Reduced False-positive Recall
Lunit Releases Its AI Online to Support Healthcare Professionals Manage COVID-19
Lunit to Present Findings on the Predictive Power of AI-based Analysis of Immune Phenotype at ASCO 2020
Lunit INSIGHT MMG, an AI Solution for Breast Cancer Detection, Now CE Certified
AI Solution for COVID-19, Developed by Medical AI Firm Lunit, Now Has Users in More Than 10 Countries
Lunit at ECR 2020: Providing Virtual Exhibition and Online Presentations
Emergent Connect Partners with Lunit to Provide Cloud Based AI Solutions
AI Analysis Can Improve Lung Cancer Detection on Chest Radiographs
AI has Added Value in Insurance Underwriting Process, Recent Pilot Project Between Lunit and Cathay Financial Innovation Lab Reveals
RSNA 2020--Lunit Collaborates with Global Giants in Presenting its AI Solution at Virtual Booths of GE Healthcare, FujiFilm, and Sectra
AI Proves Its Value in Assistance for Emergency Cases-- With Higher Accuracy and Timely Reporting Time of Chest Radiographs
Lunit Expands Collaboration with GE Healthcare to Advance AI Adoption across Healthcare Industry
AI Can Offer Fast and Reliable Examination to Triage COVID-19 Patients-- A Multicenter Retrospective Study Reveals
Recent Studies Reveal High Performance of Lunit AI in Breast Cancer Detection
South Korean Medical AI Provider and PACS Leader Enters Indonesian Market, to Help COVID-19 Screening and Diagnosis
What do the medical journals say about AI-powered mammography?
Research Using Lunit Demo Website
Lunit Presents AI-powered Pathologic Classification of Immune Phenotype that Predicts Response to Immunotherapy at USCAP 2021
What do the medical journals say about AI-powered chest x-ray interpretation?
Join our webinar with Dr. Fredrik Strand
From retrospective to prospective trials of AI in breast cancer screening
AACR 2021 - Lunit Presents Abstracts Demonstrating the Potential of its AI Biomarker in Cancer Treatment
Will AI Identify Breast Cancer Better Than Radiologists in Actual Clinical Screening?
Case of the Month | Where Is Breast Cancer?
AI-based Analysis of Cancer Tissue Predicts Response to Immunotherapy--Findings to Be Presented at ASCO 2021